Professional Information

Education

Bio

Dr. Bartus has spent the majority his career in industry, participating in the R&amp;D of more than a dozen novel treatments that progressed into human clinical trials, nearly half of which received FDA approval. Additionally, he has published over 250 scientific papers, is listed by the Institute of Scientific Information (ISI) as a “Highly Cited Researcher” (placing him in top 0.5% of all scientists), was the founding/inaugural Editor-in-Chief for Neurobiology of Aging (serving for a decade) and served on numerous elite panels, including for the United States Congress, FDA, the NIH and United States Secretary of HHS.
For 10+ years he was Ceregene’s Executive VP and Chief Scientific Officer, providing strategic and operational leadership for all non-clinical, clinical and regulatory activities, while leading the development of two different gene therapy/neurotrophic products that advanced into multi-center, randomized clinical trials for Alzheimer’s and Parkinson’s disease, respectively. Prior to Ceregene, Dr. Bartus spent 10-years at Alkermes where, as Sr VP he participated in the development and regulatory filings of several products including the concept, pre-clinical development and initial clinical strategy for Vivitrol® (approved for alcoholism and opiate abuse) and pulmonary-L-dopa (the lead program at Alkermes-spin-off, Civitas Therapeutics). Dr. Bartus had also previously pioneered the ‘Cholinergic Hypothesis’, leading to the first four drugs approved for Alzheimer’s.